Nkarta NKTX
NASDAQ NKTX
$2.66 +0.19 (+7.69%)
At close: Aug 21, 2026 · 4:00 PM EDT

Nkarta (NKTX) Liabilities and Shareholders Equity (2019 - 2026)

Nkarta (NKTX) posted quarterly Liabilities and Shareholders Equity of $372.1 million for Q1 2026, down 20.94% year-over-year from $470.6 million in Q1 2025, and down 7.95% quarter-over-quarter from $404.2 million in Q4 2025.

Nkarta (NKTX) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

Nkarta's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $372.1 million for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity fell 20.94% year-over-year to $372.1 million; the TTM figure through Mar 2026 stood at $1.7 billion (down 19.73% YoY), while the FY2025 annual figure was $404.2 million, down 19.35% from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 stood at $372.1 million, down from $404.2 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $576.9 million in Q1 2024, with the low at $306.3 million in Q1 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $458.2 million (2023), against an average of $455.6 million.
  • The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity jumped 72.67% in 2022, then slipped 20.94% in 2026.
  • Nkarta's Liabilities and Shareholders Equity stood at $472.9 million in 2022, then slipped by 19.89% to $378.9 million in 2023, then jumped by 32.28% to $501.2 million in 2024, then fell by 19.35% to $404.2 million in 2025, then decreased by 7.95% to $372.1 million in 2026.
  • Business Quant data shows NKTX's Liabilities and Shareholders Equity at $372.1 million in Q1 2026, $404.2 million in Q4 2025, and $427.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 10.96 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 9.18 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 5.56 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 25.60 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 2.10 Bn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 19.82 Bn
10 Nkarta 201.14 Mn 201.14 Mn - 337.65 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 337.65 Mn
Mar 31, 2026 372.07 Mn
Dec 31, 2025 404.21 Mn
Sep 30, 2025 427.24 Mn
Jun 30, 2025 448.31 Mn
Mar 31, 2025 470.61 Mn
Dec 31, 2024 501.20 Mn
Sep 30, 2024 532.03 Mn
Jun 30, 2024 554.09 Mn
Mar 31, 2024 576.94 Mn
Dec 31, 2023 378.89 Mn
Sep 30, 2023 405.86 Mn
Jun 30, 2023 429.04 Mn
Mar 31, 2023 458.17 Mn
Dec 31, 2022 472.94 Mn
Sep 30, 2022 503.80 Mn
Jun 30, 2022 503.64 Mn
Mar 31, 2022 306.30 Mn
Dec 31, 2021 273.90 Mn
Sep 30, 2021 292.47 Mn